newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288

  • Ascentage Pharma announced that its novel BTK-targeted protein degrader APG-3288 received IND clearance from the China CDE following U.S. FDA approval.
  • The company will conduct a multicenter, open-label Phase I study to evaluate the safety, tolerability, PK profile, & preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies.
  • APG-3288 utilizes proprietary PROTAC technology to induce degradation of both wild-type BTK & BTK mutants associated with resistance to existing inhibitors, addressing unmet clinical needs.
  • This clearance strengthens Ascentage Pharma's pipeline in hematologic malignancies & lays a foundation for potential combinations with other assets like Olverembatinib & Lisaftoclax.
  • CMO Yifan Zhai stated the company will expeditiously advance global clinical development for APG-3288 to bring this innovative therapeutic to patients in China & globally as soon as possible.
  • APG-3288 remains under investigation & has not yet received final approval from the U.S. FDA or China CDE for commercial use.